1.	Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA031, NCT00540514
2.	Phase III Randomized Study of Paclitaxel Versus Paclitaxel Albumin-Stabilized Nanoparticle Formulation Versus Ixabepilone With or Without Bevacizumab in Patients With Stage IIIC or IV Breast Cancer (The ixabepilone arm has been closed as of 8/15/11) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
3.	Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA046, NCT00844649
4.	A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: CA033, NCT00864253
5.	Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA015-0, NCT00073723
6.	Phase I/II Study of Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (ABI-007) in Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03111, ABI-CA015, NCT00077246
7.	Gemcitabine (GEMZAR) Plus ABI-007 (ABRAXANE)In Patients With Advanced Metastatic Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA040, NCT00398086
8.	Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: DOXIL, NCT00442260
9.	A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 19 and over Sponsor: Other Protocol IDs: HCI53993, NCT00748553
10.	ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA013-0, NCT00046514
11.	Phase II Study of ABI-007 in Patients With Inoperable Locally Recurrent or Metastatic Melanoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0309060, ABI-CA014, NCT00081042
12.	Phase II Study of ABI-007, Carboplatin, and Trastuzumab (Herceptin®) in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-04018, ABI-CA016, NCT00085605
13.	ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000423195, U10CA025224, N0531, 855-05, N0433, NCCTG-N0531, NCT00110084
14.	Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NSABP FB-AX-003, NCT00110695
15.	Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SCRI BRE 73, B9E-US-X437, NCT00193206
16.	A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: I-04-012, NCT00251472
17.	Neoadjuvant Treatment of Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UCI 05-38, NCT00254592
18.	Phase II Study of ABI-007 in Patients With Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: GOG-0127V, GOG-0127V, NCT00309959
19.	An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA028, NCT00274443
20.	Phase II Trial Comparing ABI-007 to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA024, NCT00274456
21.	Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UCI 05-46, NCT00319839
22.	Phase II Study of Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation (ABI-007) in Patients With Unresectable Stage IV Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N057E, N057E, NCT00404235
23.	Phase II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation (ABI-007; Abraxane®) and Bevacizumab in Women With Recurrent or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: PREMIERE-AVF3678s, PREMIERE-20061500, GENENTECH-PREMIERE-AVF3678s, ABRAXIS-PREMIERE-AVF3678s, NCT00404404
24.	Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SCRI BRE 83, NCT00392392
25.	ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA043, NCT00394082